January 18, 2022

Samsung Biologics, GreenLight to produce COVID vaccine for Africa

PUBLISHED : November 26, 2021 - 18:08

UPDATED : November 26, 2021 - 18:08

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms


Samsung Biologics and Boston-based biotech firm GreenLight Biosciences have teamed up to help make COVID-19 vaccines more accessible to people in poor countries, especially in Africa, the Korean pharmaceutical company said on Nov. 25.

Under a contract manufacturing deal signed earlier in the day, Samsung Biologics will produce drug substances for GreenLight’s messenger RNA COVID-19 vaccine candidate.

The drugmaking unit of Samsung Group said it is adding new production facilities to its plant in Songdo, Incheon, with the aim of getting manufacturing approval from the US Food and Drug Administration by the first half of next year.

As part of the deal, the two companies also agreed to beef up research and manufacturing efforts to distribute more COVID-19 vaccines for underdeveloped countries.

GreenLight Bioscience plans to finalize a separate partnership deal with a local partner in Africa and to start the phase 1 trials for clinical use as early as from the first quarter of next year.

“We are delighted to partner with GreenLight to leverage our expertise in manufacturing a messenger RNA COVID-19 vaccine candidate to better serve patients in lower income countries,” said John Rim, CEO of Samsung Biologics. “We will actively support GreenLight’s efforts to contribute to expanding global vaccine distribution.”

By Kang Jae-eun (

  • 페이스북
  • 트위터
  • sms
Herald Corporation|CEO : Jeon Chang-hyeop
Publisher. Editor : Jeon Chang-hyeop
Chief Privacy Officer & Juvenile Protection Manager : Kim Young-won
Title : The Investor|Date of registration : 2015.04.28
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0114|Business info
Gov’t registration No. Seoul 아04099